BeStock  
Stocks › Biotechnology › DNLI

Denali Therapeutics DNLI

US equityMarket cap rank #2440Biotechnology
$18.45 +$0.25 (+1.37%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $18.45 0.00%
Open$17.97
Prev close$18.20
Day range$17.92 – $18.85
Volume2.63M
Market cap$2.96B
P/E (TTM)–
Dividend yield–

Earnings

QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q33 Nov 2026After Market±15.8%+7.76%Within range
2026/Q26 Aug 2026After Market±11.3%+0.40%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q3, ended Sep 2026

Revenue$17.78M
Operating profit-$126.75M+7.8% YoY
Net profit$70.13M+155.3% YoY
Diluted EPS$0.37+150.0% YoY
Free cash flow-$125.65M-18.6% YoY
Operating cash flow-$117.44M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$3.6MJun '26$17.8MSep '26

Net profit, last 8 quarters

$-114.8MDec '24$-133.0MMar '25$-124.1MJun '25$-126.9MSep '25$-128.5MDec '25$-128.4MMar '26$-127.6MJun '26$70.1MSep '26

Profitability & balance sheet

Gross margin98.9%
Operating margin-2,488.1%
Net margin-1,470.5%
Return on equity-33.9%
Return on assets-27.2%
Return on invested capital-35.1%
Current ratio6.21
Liabilities / assets26.2%
Cash & investments$516.20M
Total debt$19.28M
Net cash (debt)$496.92M

Discussion

No comments yet — be the first to weigh in on DNLI.

Sign in to join the discussion.

Scroll to Top